Do analysts prefer REVB or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is REVB or PRFX more profitable?

PainReform's return on equity of 0.00% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -100.19% -82.72% PainReform N/A N/A N/A

Do analysts prefer VCNX or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VCNX or PRFX more profitable?

Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% PainReform N/A N/A N/A

Does the media refer more to VCNX or PRFX?

In the previous week, PainReform had 2 more articles in the media than Vaccinex. MarketBeat recorded 3 mentions for PainReform and 1 mentions for Vaccinex. PainReform's average media sentiment score of 0.92 beat Vaccinex's score of 0.00 indicating that PainReform is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PainReform 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RDHL or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, RDHL or PRFX?

Redhill Biopharma has higher revenue and earnings than PainReform. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Redhill Biopharma $290K 10.80 -$430K N/A N/A PainReform $20K 35.58 -$5.02M -$736.66 N/A

Is RDHL or PRFX more profitable?

Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A PainReform N/A N/A N/A

Does the media refer more to RDHL or PRFX?

In the previous week, Redhill Biopharma and Redhill Biopharma both had 3 articles in the media. PainReform's average media sentiment score of 0.92 beat Redhill Biopharma's score of 0.21 indicating that PainReform is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PainReform 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend JUNS or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, JUNS or PRFX?

Jupiter Neurosciences is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jupiter Neurosciences $20K 152.88 -$8.65M -$19.12 N/A PainReform $20K 35.58 -$5.02M -$736.66 N/A

Is JUNS or PRFX more profitable?

Company Net Margins Return on Equity Return on Assets Jupiter Neurosciences N/A N/A -246.66% PainReform N/A N/A N/A

Does the media refer more to JUNS or PRFX?

In the previous week, Jupiter Neurosciences had 1 more articles in the media than PainReform. MarketBeat recorded 4 mentions for Jupiter Neurosciences and 3 mentions for PainReform. PainReform's average media sentiment score of 0.92 beat Jupiter Neurosciences' score of 0.53 indicating that PainReform is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jupiter Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PainReform 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CASI or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CASI or PRFX more profitable?

PainReform has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals -183.93% N/A -131.54% PainReform N/A N/A N/A

Does the media favor CASI or PRFX?

In the previous week, PainReform had 2 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 3 mentions for PainReform and 1 mentions for CASI Pharmaceuticals. PainReform's average media sentiment score of 0.92 beat CASI Pharmaceuticals' score of 0.00 indicating that PainReform is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CASI Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PainReform 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

PainReform (PRFX) Competitors

$0.83 +0.01 (+1.10%)

As of 01:23 PM Eastern

Compare

PRFX vs. REVB, VCNX, RDHL, JUNS, and CASI

Should you buy PainReform stock or one of its competitors? PainReform's main competitors and comparable companies include Revelation Biosciences (REVB), Vaccinex (VCNX), Redhill Biopharma (RDHL), Jupiter Neurosciences (JUNS), and CASI Pharmaceuticals (CASI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PainReform compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, PainReform had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 3 mentions for PainReform and 2 mentions for Revelation Biosciences. PainReform's average media sentiment score of 0.92 beat Revelation Biosciences' score of 0.41 indicating that PainReform is being referred to more favorably in the news media.

Company	Overall Sentiment
Revelation Biosciences	Neutral
PainReform	Positive

Revelation Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, PainReform has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

PainReform has higher revenue and earnings than Revelation Biosciences. Revelation Biosciences is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A
PainReform	$20K	35.58	-$5.02M	-$736.66	N/A

PainReform's return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-100.19%	-82.72%
PainReform	N/A	N/A	N/A

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

PainReform beats Revelation Biosciences on 10 of the 11 factors compared between the two stocks.

How does PainReform compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

PainReform has lower revenue, but higher earnings than Vaccinex. Vaccinex is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.04	-$20.25M	-$48.27	N/A
PainReform	$20K	35.58	-$5.02M	-$736.66	N/A

Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, PainReform has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

In the previous week, PainReform had 2 more articles in the media than Vaccinex. MarketBeat recorded 3 mentions for PainReform and 1 mentions for Vaccinex. PainReform's average media sentiment score of 0.92 beat Vaccinex's score of 0.00 indicating that PainReform is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaccinex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PainReform	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 51.5% of Vaccinex shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
PainReform	N/A	N/A	N/A

Summary

PainReform beats Vaccinex on 7 of the 12 factors compared between the two stocks.

How does PainReform compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

In the previous week, Redhill Biopharma and Redhill Biopharma both had 3 articles in the media. PainReform's average media sentiment score of 0.92 beat Redhill Biopharma's score of 0.21 indicating that PainReform is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Redhill Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PainReform	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Redhill Biopharma has a beta of 4.91, meaning that its stock price is 391% more volatile than the broader market. Comparatively, PainReform has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
PainReform	N/A	N/A	N/A

Redhill Biopharma has higher revenue and earnings than PainReform.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	10.80	-$430K	N/A	N/A
PainReform	$20K	35.58	-$5.02M	-$736.66	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PainReform beats Redhill Biopharma on 4 of the 7 factors compared between the two stocks.

How does PainReform compare to Jupiter Neurosciences?

Jupiter Neurosciences (NASDAQ:JUNS) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Jupiter Neurosciences is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	152.88	-$8.65M	-$19.12	N/A
PainReform	$20K	35.58	-$5.02M	-$736.66	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Jupiter Neurosciences had 1 more articles in the media than PainReform. MarketBeat recorded 4 mentions for Jupiter Neurosciences and 3 mentions for PainReform. PainReform's average media sentiment score of 0.92 beat Jupiter Neurosciences' score of 0.53 indicating that PainReform is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jupiter Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PainReform	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jupiter Neurosciences has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, PainReform has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	N/A	-246.66%
PainReform	N/A	N/A	N/A

37.3% of PainReform shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Jupiter Neurosciences beats PainReform on 5 of the 9 factors compared between the two stocks.

How does PainReform compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

PainReform has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
PainReform	N/A	N/A	N/A

PainReform has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
PainReform	$20K	35.58	-$5.02M	-$736.66	N/A

CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, PainReform has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, PainReform had 2 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 3 mentions for PainReform and 1 mentions for CASI Pharmaceuticals. PainReform's average media sentiment score of 0.92 beat CASI Pharmaceuticals' score of 0.00 indicating that PainReform is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CASI Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PainReform	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PainReform beats CASI Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

Get PainReform News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRFX vs. The Competition

Export

Metric	PainReform	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$719K	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	0.00	807.81	275.40	25.37
Price / Sales	35.97	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	0.04	9.21	10.55	5.95
Net Income	-$5.02M	$2.84B	$3.50B	$380.75M
7 Day Performance	-5.78%	-4.00%	-3.92%	-3.96%
1 Month Performance	-3.89%	-8.07%	-8.30%	-6.81%
1 Year Performance	-86.98%	-5.86%	2.35%	-4.58%

PainReform Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRFX PainReform	1.2617 of 5 stars	$0.83 +1.1%	N/A	-86.5%	$719K	$20K	N/A	7	Positive News Short Interest Decrease Gap Up
REVB Revelation Biosciences	0.637 of 5 stars	$0.83 +10.1%	N/A	-86.4%	$3M	N/A	N/A	9	Gap Down
VCNX Vaccinex	N/A	$1.15 +3.4%	N/A	+100.3%	$2.99M	$388K	N/A	40	Gap Down
RDHL Redhill Biopharma	0.832 of 5 stars	$0.47 -2.1%	N/A	-68.4%	$2.94M	$290K	N/A	210	News Coverage Gap Up
JUNS Jupiter Neurosciences	0.4434 of 5 stars	$2.84 -0.7%	N/A	-97.1%	$2.61M	$20K	N/A	5

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRFX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PainReform (PRFX) Competitors

PRFX vs. REVB, VCNX, RDHL, JUNS, and CASI

How does PainReform compare to Revelation Biosciences?

Summary

How does PainReform compare to Vaccinex?

Summary

How does PainReform compare to Redhill Biopharma?

Summary

How does PainReform compare to Jupiter Neurosciences?

Summary

How does PainReform compare to CASI Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PainReform (PRFX) Competitors

PRFX vs. REVB, VCNX, RDHL, JUNS, and CASI

How does PainReform compare to Revelation Biosciences?

Do analysts prefer REVB or PRFX?

Does the media refer more to REVB or PRFX?

Which has more risk & volatility, REVB or PRFX?

Which has better valuation and earnings, REVB or PRFX?

Is REVB or PRFX more profitable?

Do insiders & institutionals believe in REVB or PRFX?

Summary

How does PainReform compare to Vaccinex?

Which has preferable earnings & valuation, VCNX or PRFX?

Which has more volatility and risk, VCNX or PRFX?

Does the media refer more to VCNX or PRFX?

Do institutionals & insiders believe in VCNX or PRFX?

Do analysts prefer VCNX or PRFX?

Is VCNX or PRFX more profitable?

Summary

How does PainReform compare to Redhill Biopharma?

Does the media refer more to RDHL or PRFX?

Which has more risk & volatility, RDHL or PRFX?

Do insiders & institutionals believe in RDHL or PRFX?

Is RDHL or PRFX more profitable?

Which has stronger valuation & earnings, RDHL or PRFX?

Do analysts prefer RDHL or PRFX?

Summary

How does PainReform compare to Jupiter Neurosciences?

Which has stronger earnings & valuation, JUNS or PRFX?

Do analysts recommend JUNS or PRFX?

Does the media refer more to JUNS or PRFX?

Which has more risk & volatility, JUNS or PRFX?

Is JUNS or PRFX more profitable?

Do insiders and institutionals believe in JUNS or PRFX?

Summary

How does PainReform compare to CASI Pharmaceuticals?

Is CASI or PRFX more profitable?

Which has better valuation and earnings, CASI or PRFX?

Which has more volatility and risk, CASI or PRFX?

Do insiders & institutionals hold more shares of CASI or PRFX?

Does the media favor CASI or PRFX?

Do analysts prefer CASI or PRFX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools